Patents by Inventor Anders WAAS

Anders WAAS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of dextran sulfate
    Patent number: 10925890
    Abstract: The present embodiments relate to the use of dextran sulfate having an average molecular weight below 10 000 Da for inducing angiogenesis in a subject and for increasing blood flow in a subject suffering from ischemia.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: February 23, 2021
    Assignee: TX MEDIC AB
    Inventors: Anders Waas, Lars Bruce, Adam Bruce
  • USE OF DEXTRAN SULFATE
    Publication number: 20190381090
    Abstract: The present embodiments relate to the use of dextran sulfate having an average molecular weight below 10 000 Da for inducing angiogenesis in a subject and for increasing blood flow in a subject suffering from ischemia.
    Type: Application
    Filed: August 20, 2019
    Publication date: December 19, 2019
    Inventors: Anders WAAS, Lars BRUCE, Adam BRUCE
  • Use of dextran sulfate having an average molecular weight below 10000 DA for inducing angiogenesis in a subject
    Patent number: 10485817
    Abstract: The present embodiments relate to the use of dextran sulfate having an average molecular weight below 10 000 Da for inducing angiogenesis in a subject and for increasing blood flow in a subject suffering from ischemia.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: November 26, 2019
    Assignee: TX MEDIC AB
    Inventors: Anders Waas, Lars Bruce, Adam Bruce
  • Use of dextran sulfate
    Patent number: 10478451
    Abstract: The present embodiments relate to the use of dextran sulfate formulated for systemic administration for treatment, inhibition or prevention of cardiac fibrosis in a subject.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: November 19, 2019
    Assignee: TX MEDIC AB
    Inventors: Lars Bruce, Adam Bruce, Anders Waas
  • Dextran sulfate for use in mobilization of cells
    Patent number: 10258642
    Abstract: Dextran sulfate in a range of 3500 and 9500 Da is employed to mobilize cells, such as stem and/or progenitor cells and certain white blood cells, in particular lymphocytes, into the peripheral blood of a subject. Dextran sulfate has a very fast cell mobilizing effect that implies that any cell harvest can be started almost immediately following dextran sulfate administration.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: April 16, 2019
    Assignee: TX MEDIC AB
    Inventors: Anders Waas, Ida Duprez
  • NEW USE OF DEXTRAN SULFATE
    Publication number: 20180221403
    Abstract: The present embodiments relate to the use of dextran sulfate formulated for systemic administration for treatment, inhibition or prevention of cardiac fibrosis in a subject.
    Type: Application
    Filed: July 15, 2016
    Publication date: August 9, 2018
    Applicant: TX Medic AB
    Inventors: Lars BRUCE, Adam BRUCE, Anders WAAS
  • THE USE OF DEXTRAN SULFATE HAVING AN AVERAGE MOLECULAR WEIGHT BELOW 10000 DA FOR INDUCING ANGIOGENESIS IN A SUBJECT
    Publication number: 20170151275
    Abstract: The present embodiments relate to the use of dextran sulfate having an average molecular weight below 10 000 Da for inducing angiogenesis in a subject and for increasing blood flow in a subject suffering from ischemia.
    Type: Application
    Filed: June 11, 2015
    Publication date: June 1, 2017
    Inventors: Anders WAAS, Lars BRUCE, Adam BRUCE
  • DEXTRAN SULFATE FOR USE IN MOBILIZATION OF CELLS
    Publication number: 20160120897
    Abstract: Dextran sulfate in a range of 3500 and 9500 Da is employed to mobilize cells, such as stem and/or progenitor cells and certain white blood cells, in particular lymphocytes, into the peripheral blood of a subject. Dextran sulfate has a very fast cell mobilizing effect that implies that any cell harvest can be started almost immediately following dextran sulfate administration.
    Type: Application
    Filed: May 12, 2014
    Publication date: May 5, 2016
    Applicant: TX MEDIC AB
    Inventors: Anders WAAS, Ida DUPREZ